Phase II, open-label study to assess the safety and immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021–2022 Formulation and a third dose of mRNA-1273 COVID-19 vaccine (Moderna) administered either concomitantly or singly in adults 65 years of age and older previously vaccinated with a 2-dose schedule of mRNA-1273 vaccine

Izikson, Ruvim

i

Phase II, open-label study to assess the safety and immunogenicity of Fluzone® High-Dose Quadrivalent (Influenza Vaccine), 2021–2022 Formulation and a third dose of mRNA-1273 COVID-19 vaccine (Moderna) administered either concomitantly or singly in adults 65 years of age and older previously vaccinated with a 2-dose schedule of mRNA-1273 vaccine

Public Domain

October 20, 2021
By Izikson, Ruvim
Series: ACIP: Influenza

File Language:

English

Details

Personal Author:

Izikson, Ruvim
Corporate Authors:

Sanofi Pasteur.
Description:

02-influenza-izikson-508.pdf
Subjects:

COVID-19 Vaccines Influenza Vaccines
Series:

ACIP: Influenza
Document Type:

Still Image
Name as Subject:

ACIP meeting: 2021 Oct 20 ; ACIP meeting: 2021 Oct 20
Genre:

Presentation ; Conference Publications
Volume:

202113
Issue:

120302
Collection(s):

Advisory Committee on Immunization Practices (ACIP)
Main Document Checksum:

urn:sha-512:d3cdd2bd5c056448c929e1b7940b9e68cff6861a7543eaa54b0b9bc0f5138e406afea5a8dbc40c5e7345575d42d233067a9f0a2813e36e33ca8fc1c5b8472c29
Download URL:

https://stacks.cdc.gov/view/cdc/110912/cdc_110912_DS1.pdf
File Type:

[PDF - 749.57 KB ]

File Language:

English

ON THIS PAGE

Details Related Documents

CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.